These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 10500606)

  • 1. Prophylaxis of cytomegalovirus disease with intravenous ganciclovir in renal transplantation.
    Sancho A; Górriz JL; Crespo JF; Avila A; Alcaraz MJ; García Ramos JL; Pallardó LM
    Transplant Proc; 1999 Sep; 31(6):2337-8. PubMed ID: 10500606
    [No Abstract]   [Full Text] [Related]  

  • 2. Prophylaxis of cytomegalovirus primary infection with short-term ganciclovir therapy.
    Lauzurica R; Bayés B; Frías C; Hernández A; Jimenez A; Fontseré N; Romero R
    Transplant Proc; 2003 Aug; 35(5):1751-2. PubMed ID: 12962781
    [No Abstract]   [Full Text] [Related]  

  • 3. Failure of ganciclovir prophylaxis of primary cytomegalovirus disease in immunologic high-risk recipients.
    Conti DJ; Isenberg A; Shen GK; Hahn A; Singh TP
    Transplant Proc; 1998 Jun; 30(4):1314-5. PubMed ID: 9636533
    [No Abstract]   [Full Text] [Related]  

  • 4. Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy.
    Morales E; Andrés A; González E; Herrero JC; Muñoz MA; Ortiz M; Espejo B; Lumbreras C; Morales JM; Aguado JM
    Transplant Proc; 2002 Feb; 34(1):73-4. PubMed ID: 11959191
    [No Abstract]   [Full Text] [Related]  

  • 5. Ganciclovir prophylaxis of cytomegalovirus disease.
    Conti DJ; Shen G; Singh T; Isenberg A; Freed BM
    Transplant Proc; 1997; 29(1-2):804-6. PubMed ID: 9123534
    [No Abstract]   [Full Text] [Related]  

  • 6. Prevention of cytomegalovirus disease after heart transplantation: preemptive therapy with 7 days' intravenous ganciclovir.
    Paniagua MJ; Crespo-Leiro MG; De la Fuente L; Tabuyo T; Mosquera I; Cañizares A; Naya C; Fariña P; Juffé A; Castro-Beiras A
    Transplant Proc; 2002 Feb; 34(1):69-70. PubMed ID: 11959189
    [No Abstract]   [Full Text] [Related]  

  • 7. Emergence of cytomegalovirus resistance to ganciclovir after oral maintenance treatment in a renal transplant recipient.
    Bienvenu B; Thervet E; Bedrossian J; Scieux C; Mazeron MC; Thouvenot D; Legendre C
    Transplant Proc; 2000 Mar; 32(2):407. PubMed ID: 10715457
    [No Abstract]   [Full Text] [Related]  

  • 8. Eradication of cytomegalovirus reactivation disease using high-dose acyclovir and targeted intravenous ganciclovir in kidney and kidney/pancreas transplantation.
    Shen GK; Alfrey EJ; Knoppel CL; Dafoe DC; Scandling JD
    Transplantation; 1997 Sep; 64(6):931-3. PubMed ID: 9326425
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytomegalovirus prophylaxis with ganciclovir in kidney transplant recipients receiving induction antilymphocyte antibodies.
    Said T; Nampoory MR; Johny KV; Pacsa AS; Mini Abraham P; Nair MP; Abdel-Haleem M; Samhan M; Al-Mousawi M
    Transplant Proc; 2004; 36(6):1847-9. PubMed ID: 15350495
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preemptive oral ganciclovir therapy versus prophylaxis to prevent symptomatic cytomegalovirus infection after kidney transplantation.
    Jung C; Engelmann E; Borner K; Offermann G
    Transplant Proc; 2001; 33(7-8):3621-3. PubMed ID: 11750538
    [No Abstract]   [Full Text] [Related]  

  • 11. Kidney recipient CMV incidence in the gancyclovir era: monitoring viral DNA by a CMV-PCR assay.
    Cirocco RE; Ciancio G; Esquenazi V; Burke GW; Miller J
    Transplant Proc; 1999; 31(1-2):1362-3. PubMed ID: 10083604
    [No Abstract]   [Full Text] [Related]  

  • 12. Monitoring of CMV infection after renal transplantation: serology, culture, and viral DNA detection by hybrid capture.
    Flechner SM; Avery RK; Fisher R; Mastroianni B; Papajcik D; O'Malley KJ; Goormastic M; Goldfarb DA; Modlin CS; Novick AC
    Transplant Proc; 1999; 31(1-2):1255-7. PubMed ID: 10083560
    [No Abstract]   [Full Text] [Related]  

  • 13. Cytomegalovirus prophylaxis by ganciclovir followed by high-dose acyclovir in renal transplantation: a randomized, controlled trial.
    Pouteil-Noble C; Megas F; Chapuis F; Bosshard S; Colin C; Hadj-Aissa A; Pozet N; Martin X; Lefrançois N; Garnier JL; Aymard M; Touraine JL
    Transplant Proc; 1996 Oct; 28(5):2811. PubMed ID: 8908072
    [No Abstract]   [Full Text] [Related]  

  • 14. Valacyclovir for cytomegalovirus prophylaxis reduces the risk of acute renal allograft rejection.
    Reischig T; Jindra P; Mares J; Cechura M; Svecová M; Hes O; Opatrný K; Treska V
    Transplantation; 2005 Feb; 79(3):317-24. PubMed ID: 15699762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Effectiveness of preemptive therapy with ganciclovir in recipients of renal transplants at high risk (R-/D+) for the development of cytomegalovirus disease].
    Aranda-Verástegui F; Alberú J; Soto-Ramírez LE; González-Aguirre H; Muñoz Trejo T; Mancilla E; Díliz H; Correa-Rotter R; Sierra-Madero J
    Rev Invest Clin; 2002; 54(3):198-203. PubMed ID: 12183888
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacoeconomic analysis of preemptive gancyclovir therapy in the prevention of cytomegalovirus infections in high-risk renal graft recipients.
    Chak WL; Choi KS; Wong KM; Chan YH; Chau KF; Li CS
    Transplant Proc; 2003 Feb; 35(1):280-1. PubMed ID: 12591399
    [No Abstract]   [Full Text] [Related]  

  • 17. Early ganciclovir therapy effectively controls viremia and avoids the need for cytomegalovirus (CMV) prophylaxis in renal transplant patients with cytomegalovirus antigenemia.
    Gotti E; Suter F; Baruzzo S; Perani V; Moioli F; Remuzzi G
    Clin Transplant; 1996 Dec; 10(6 Pt 1):550-5. PubMed ID: 8996777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ganciclovir prophylaxis delays but does not prevent cytomegalovirus infection in renal transplant recipients.
    Israni A; Krok K; Cohen D; Blumberg E; Bloom RD
    Transplant Proc; 2004 Dec; 36(10):3019-24. PubMed ID: 15686685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cytomegalovirus infection in kidney transplantation: prophylaxis and management.
    Bulinski P; Toledo-Pereyra LH; Dalal S; Hernandez G
    Transplant Proc; 1996 Dec; 28(6):3310-1. PubMed ID: 8962286
    [No Abstract]   [Full Text] [Related]  

  • 20. Costs and outcomes of prolonged cytomegalovirus prophylaxis to cover the enhanced immunosuppression phase following lung transplantation.
    Gerbase MW; Dubois D; Rothmeier C; Spiliopoulos A; Wunderli W; Nicod LP
    Chest; 1999 Nov; 116(5):1265-72. PubMed ID: 10559085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.